Cocrystal Pharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
COCP$0.98-1.0%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Checking your notes…
(in thousands)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2023 | 10,174 | $10 | $342,288 | $(315,914) | $26,384 |
| Stock-based compensation | - | - | 643 | - | 643 |
| Net loss | - | - | - | (17,504) | (17,504) |
| Balance as of December 31, 2024 | 10,174 | $10 | $342,931 | $(333,418) | $9,523 |
| Sale of common stock in ATM, net of transaction costs | 85 | - | 154 | - | 154 |
| Stock-based compensation | - | - | 270 | - | 270 |
| Share issuance from RSU award | 17 | - | - | - | - |
| Sale of common stock and warrants, net of transaction costs | 3,508 | 3 | 5,212 | - | 5,215 |
| Net loss | - | - | - | (8,831) | (8,831) |
| Balance as of December 31, 2025 | 13,784 | $13 | $348,567 | $(342,249) | $6,331 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.